Clinical Trial Update: [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This ongoing University of Washington-led study is a Phase 1/2 trial evaluating the [18F]FTT PET imaging agent to quantify PARP expression in metastatic breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• [18F]FTT PET tracer

Snippet

Sponsor: University of Washington | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1, Phase 2 | Status: RECRUITING